Kalpana Morparia - Dr Reddys Non-Executive Independent Director

RDY
 Stock
  

USD 55.84  0.45  0.81%   

  Director
Ms. Kalpana Morparia serves as NonExecutive Independent Director of Dr. Reddy Laboratories Ltd. Ms. Kalpana Morparia is the Chair person of J.P. Morgan, South and Southeast Asia. Ms. Morparia is a member of J.P. Morgans Asia Pacifi c Management Committee. Prior to joining J.P. Morgan India, Ms. Morparia served as Vice Chair on the Boards of ICICI Group Companies and was the Joint Managing Director of ICICI Group from 2001 to 2007. She was recognized by several nationaland international media for her role as one of the leading women professionals. Ms. Morparia holds directorship in Hindustan Unilever Limitedand J.P. Morgan Services India Private Limited in India and Philip Morris International Inc. in USA. She is also a member of the Governing Board of Bharti Foundation. A graduate in science and law from Mumbai University, India. Ms. Morparia has served on several committees constituted by the Government of India.
Age: 71  Director Since 2007  MBA    
91 40 4900 2900  https://www.drreddys.com
Morparia is a member of J P Morgan’s Asia Pacifi c Management Committee. Prior to joining J.P. Morgan India, Ms. Morparia served as Vice Chair on the Boards of ICICI Group Companies and was the Joint Managing Director of ICICI Group from 2001 to 2007. She was recognised by several international and national media for her role as one of the leading women professionals. She serves as an Independent Director on the Boards of Philip Morris International Inc., USA, Hindustan Unilever Limited and as a NonExecutive Director on J P Morgan Asset Management India Private Limited and J P Morgan Services India Private Limited. She is also a Member of the Governing Board of Bharti Foundation. She is a graduate in Science and Law from Bombay University.

Dr Reddys Management Efficiency

Dr Reddys Laboratories has Return on Asset of 8.11 % which means that on every $100 spent on asset, it made $8.11 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 14.64 %, implying that it generated $14.64 on every 100 dollars invested. Dr Reddys management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 28.16 B in debt with debt to equity (D/E) ratio of 0.15, which may show that the company is not taking advantage of profits from borrowing. Dr Reddys Laboratories has a current ratio of 1.95, which is typical for the industry and considered as normal. Debt can assist Dr Reddys until it has trouble settling it off, either with new capital or with free cash flow. So, Dr Reddys' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dr Reddys Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dr Reddys to invest in growth at high rates of return. When we think about Dr Reddys' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Henrietta ForeExxon Mobil Corp
2012
Howard BuffettCoca-Cola
2010
Alice GastChevron Corp
2012
Roderick McGearyCisco Systems
2003
Cynthia TaylorATT Inc
2013
Richard DaleyCoca-Cola
2011
Alex GorskyInternational Business Machines
2015
Sean MahoneyAlcoa Corp
2016
John McCoyATT Inc
1999
Debra ReedKlagesChevron Corp
2018
Linda HudsonBank Of America
2012
Alain BeldaInternational Business Machines
2008
Shirley JacksonInternational Business Machines
2005
John StumpfChevron Corp
2010
Frederick McNabbInternational Business Machines
2019
Stephen SangerPfizer Inc
2009
Shantanu NarayenPfizer Inc
2019
Maria LagomasinoCoca-Cola
2019
James NevelsAlcoa Corp
2016
Brian HallaCisco Systems
2007
Robert DenhamChevron Corp
2004
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 227 people. Dr Reddys Laboratories (RDY) is traded on New York Stock Exchange in USA and employs 22,739 people.

Dr Reddys Laboratories Leadership Team

Elected by the shareholders, the Dr Reddys' board of directors comprises two types of representatives: Dr Reddys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dr Reddys. The board's role is to monitor Dr Reddys' management team and ensure that shareholders' interests are well served. Dr Reddys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Reddys' outside directors are responsible for providing unbiased perspectives on the board's policies.
MARC KIKUCHI, Chief Executive Officer, North America Generics
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Patrick Aghanian, Chief Executive Officer, European Generics
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head – Chemical Technical Operations (CTO)
K Krishnan, Additional Independent Director
Shikha Sharma, Non-Executive Independent Director
Omkar Goswami, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Parag Agarwal, Chief Financial Officer - Designate
Cartikeya Reddy, Senior Vice President Head - Biologics
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of Pharmaceutical Services and Active Ingredients
Penny Wan, Additional Independent Director
G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
P Yugandhar, Global Head of Supply Chain
Hans Hasler, Additional Independent Director
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Alok Sonig, Senior Vice President & India Business Head (Generics)
K Singh, Chief Compliance Officer, Company Secretary
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Vivek Mittal, Interim Compliance Officer, General Counsel
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Anupam Puri, Non-Executive Independent Director
Mukesh Rathi, Chief Digital and Information Officer

Dr Reddys Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dr Reddys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Dr Reddys without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Currently Active Assets on Macroaxis

Additionally, take a look at Your Equity Center. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Dr Reddys Stock analysis

When running Dr Reddys Laboratories price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know Dr Reddys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.76
Market Capitalization
9.3 B
Quarterly Revenue Growth YOY
0.15
Return On Assets
0.0804
Return On Equity
0.13
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of Dr Reddys that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine Dr Reddys value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.